pharma · Nonalcoholic Steatohepatitis (NASH) · Amyotrophic Lateral Sclerosis · CORT
CORCEPT THERAPEUTICS
CORCEPT THERAPEUTICS INC
CORCEPT THERAPEUTICS clinical programs — 20 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 101 Redwood Shores Pkwy, Redwood City, California 94065, US
- Founded
- 1998
- Employees
- 756
- Programs
- 67
- Drugs
- 36
- Patents
- 120
CORCEPT THERAPEUTICS projects
20 ClinicalTrials.gov programs sponsored by CORCEPT THERAPEUTICS.
CORCEPT THERAPEUTICS has 20 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
CORT113176-652
CORCEPT THERAPEUTICS INC
Amyotrophic Lateral Sclerosis
1 trial -
CORT125134
CORCEPT THERAPEUTICS INC
Cushing's Syndrome
1 trial -
CORT125134-557
CORCEPT THERAPEUTICS INC
Gynecological Cancers
1 trial -
Dazucorilant 300 mg
CORCEPT THERAPEUTICS INC
Amyotrophic Lateral Sclerosis
1 trial -
Enzalutamide
CORCEPT THERAPEUTICS INC
Metastatic Breast Cancer
1 trial -
Exicorilant
CORCEPT THERAPEUTICS INC
Metastatic Castration-Resistant Prostate Cancer
1 trial -
Mifepristone
CORCEPT THERAPEUTICS INC
Alzheimer's Disease
1 trial -
Mifepristone
CORCEPT THERAPEUTICS INC
Central Adrenal Insufficiency
1 trial -
Mifepristone
CORCEPT THERAPEUTICS INC
Non-Small Cell Lung Cancer (NSCLC)
1 trial -
Mifepristone
CORCEPT THERAPEUTICS INC
Weight-Gain Prevention
1 trial -
Mifepristone 1200 mg daily
CORCEPT THERAPEUTICS INC
Treatment-resistant PTSD
1 trial -
Miricorilant
CORCEPT THERAPEUTICS INC
Antipsychotic-induced Weight Gain (AIWG)
1 trial -
Miricorilant
CORCEPT THERAPEUTICS INC
Nonalcoholic Steatohepatitis (NASH)
3 trials -
Miricorilant (Cohort A)
CORCEPT THERAPEUTICS INC
Nonalcoholic Steatohepatitis (NASH)
1 trial -
Miricorlilant
CORCEPT THERAPEUTICS INC
Antipsychotic-induced Weight Gain (AIWG)
1 trial -
Nenocorilant 200 mg
CORCEPT THERAPEUTICS INC
Neoplasms
1 trial -
Relacorilant
CORCEPT THERAPEUTICS INC
Recurrent Ovarian Cancer
1 trial -
Relacorilant 150 mg once daily (QD)
CORCEPT THERAPEUTICS INC
Adenocarcinoma
1 trial -
Relacorilant 150 mg once daily (QD)
CORCEPT THERAPEUTICS INC
Ovarian Cancer
1 trial -
Relacorilant with nab-paclitaxel
CORCEPT THERAPEUTICS INC
Solid Tumors
1 trial
Frequently asked questions
How many clinical projects does CORCEPT THERAPEUTICS have?
20 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.